Antiangiogenic drugs targeting the VEGF pathway have slowed metastatic disease
progression in some patients, leading to progression-free survival (PFS) and overall survival …

Lung cancer is the leading cause of cancer-related deaths worldwide. Despite growing
efforts for its early detection by screening populations at risk, the majority of lung cancer …

Background: Lung cancer screening may detect cancer that will never become symptomatic
(overdiagnosis), leading to overtreatment. Changes in size on sequential low-dose …

Although progression-based endpoints, such as progression-free survival, are often key
clinical trial endpoints for anticancer agents, the clinical meaning of “objective progression” …

Objective Advanced and recurrent diseases are the major causes of death in colon cancer.
No standard preclinical model addresses advanced disease and spontaneous metastasis …

The present disclosure provides for improved image analysis via novel deblurring and
segmentation techniques of image data. These techniques advantageously account for and …

OBJECTIVE: Understanding magnitudes of variability when measuring tumor size may be
valuable in improving detection of tumor change and thus evaluating tumor response to …

Abstract Learning Objectives After completing this course, the reader will be able to: Identify
the current indications for pazopanib and axitinib. Describe the mechanism of action and the …

The discovery in 2004 of activating mutations in the EGFR gene opened the era of
personalized medicine in thoracic oncology. Treatment with drugs that target EGFR typically …

Methods and systems are disclosed for structuring and using information pertinent to in vivo
biomarkers, specifically quantitative imaging biomarkers, using semantic web technology for …